Alison Moore is the CTO and EVP of Operations at Allogene Therapeutics Inc. She was a former Senior Vice President, Process Development at Amgen. Prior to this role, Moore served as senior vice president of Operations Technology. Moore was previously vice president of the Process and Product Engineering (P&PE) function, where she was. responsible for Process Development, Clinical Operations, and Global Operations Planning. Moore served as vice president, Corporate Manufacturing, overseeing Supply Chain, Contract Manufacturing, Global Distribution, Manufacturing Technologies, and Operations Risk Management. Before taking on this position, she was vice president, Site Operations at Amgen's Fremont, California, manufacturing facility (AFR).. Before heading up the AFR facility, Moore was a director in Chemistry, Manufacturing, and Controls Regulatory Affairs at Genentech. Prior to her time at Genentech, Moore had previously spent nine years at Amgen in various positions of increasing responsibility within the Process Development organization.. Moore holds a Ph.D. in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England. Following her doctoral degree work at Manchester University, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.
